Podcasts Health Empowered Patient Podcast Immunocytokines Platform Superagonist Activates T-cells and NK Cells to Fight Solid Tumors With Jens Hennecke SOTIO

Immunocytokines Platform Superagonist Activates T-cells and NK Cells to Fight Solid Tumors With Jens Hennecke SOTIO

Published: July 22, 2020, 8:19 p.m.

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells.

#SOTIO #immunotherapies #IL15

SOTIO.com

Download the transcript here

SOTIO